Allogene Therapeutics Inc (ALLO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29171.70 is considered Overvalued compared with the five-year average of -3.91. The fair price of Allogene Therapeutics Inc (ALLO) is between 0.76 to 2.64 according to relative valuation method. Compared to the current price of 2.65 USD , Allogene Therapeutics Inc By Overvalued By 0.46%.

Relative Value

Fair Zone

0.76-2.64

Current Price：2.65

0.46%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Allogene Therapeutics Inc (ALLO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Allogene Therapeutics Inc (ALLO) has a current Price-to-Book (P/B) ratio of 0.96. Compared to its 3-year average P/B ratio of 1.03, the current P/B ratio is approximately -6.87% higher. Relative to its 5-year average P/B ratio of 1.62, the current P/B ratio is about -41.01% higher. Allogene Therapeutics Inc (ALLO) has a Forward Free Cash Flow (FCF) yield of approximately -52.40%. Compared to its 3-year average FCF yield of -47.18%, the current FCF yield is approximately 11.07% lower. Relative to its 5-year average FCF yield of -32.39%, the current FCF yield is about 61.79% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ALLO competitors is 5840.66, providing a benchmark for relative valuation. Allogene Therapeutics Inc Corp (ALLO.O) exhibits a P/S ratio of 29171.70, which is 399.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ALLO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ALLO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ALLO currently overvalued or undervalued?

Allogene Therapeutics Inc (ALLO) is now in the Overvalued zone, suggesting that its current forward PS ratio of 29171.70 is considered Overvalued compared with the five-year average of -3.91. The fair price of Allogene Therapeutics Inc (ALLO) is between 0.76 to 2.64 according to relative valuation method. Compared to the current price of 2.65 USD, Allogene Therapeutics Inc is Overvalued By 0.46%.

What is Allogene Therapeutics Inc (ALLO) fair value?

ALLO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Allogene Therapeutics Inc (ALLO) is between 0.76 to 2.64 according to relative valuation method.

How does ALLO's valuation metrics compare to the industry average?

The average P/S ratio for ALLO's competitors is 5840.66, providing a benchmark for relative valuation. Allogene Therapeutics Inc Corp (ALLO) exhibits a P/S ratio of 29171.70, which is 399.46% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Allogene Therapeutics Inc (ALLO) as of Mar 03 2026?

As of Mar 03 2026, Allogene Therapeutics Inc (ALLO) has a P/B ratio of 0.96. This indicates that the market values ALLO at 0.96 times its book value.

What is the current FCF Yield for Allogene Therapeutics Inc (ALLO) as of Mar 03 2026?

As of Mar 03 2026, Allogene Therapeutics Inc (ALLO) has a FCF Yield of -52.40%. This means that for every dollar of Allogene Therapeutics Inc's market capitalization, the company generates -52.40 cents in free cash flow.

What is the current Forward P/E ratio for Allogene Therapeutics Inc (ALLO) as of Mar 03 2026?

As of Mar 03 2026, Allogene Therapeutics Inc (ALLO) has a Forward P/E ratio of -1.48. This means the market is willing to pay $-1.48 for every dollar of Allogene Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Allogene Therapeutics Inc (ALLO) as of Mar 03 2026?

As of Mar 03 2026, Allogene Therapeutics Inc (ALLO) has a Forward P/S ratio of 29171.70. This means the market is valuing ALLO at $29171.70 for every dollar of expected revenue over the next 12 months.

ALLO Valuation